Phosphodiesterase-4 (PDE4) is an intracellular pro-inflammatory enzyme that is considered a therapeutic target in inflammatory disorders such as psoriasis, asthma or ulcerative colitis (UC), among others. Researchers from Palisade Bio Inc. have reported preclinical data on PALI-2108, a PDE4 inhibitor prodrug, in models of UC.